Document is current
Any future updates will be listed below
-
Authors
Ekholm, Andreas
Wang, Yinxi
Vallon-Christersson, Johan
Boissin, Constance
Rantalainen, Mattias
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 2 August 2024
Accepted: 25 November 2024
First Online: 11 December 2024
Declarations
:
: The Clinseq study was approved by the Ethical Committee of Karolinska Institutet. Stockholm, Sweden, with reference 2013/1833-31/2. The SCAN-B study was approved by the Regional Ethical Review Board in Lund, Sweden (registration numbers 2009/658, 2010/383, 2012/58, 2013/459, 2014/521, 2015/277, 2016/541, 2016/742, 2016/944, 2018/267 and the Swedish Ethical Review Authority (registration numbers 2019-01252, 2024-02040-02). All patients provided written informed consent prior to enrollment. All analyses were performed in accordance with patient consent and ethical regulations and decisions. The study was further approved by the Swedish Ethical Review Authority (Etiksprovningsmyndigheten, Stockholm, Sweden, reference 2017/2106-31, with amendments 2018/1462-32 and 2019–02336).
: Not applicable.
: MR is a cofounder and shareholder of Stratipath AB. YW is employed by Stratipath AB and holds employee stock options. AE, JVC and CB declare no financial or non-financial competing interests.
